Source comparison
Weight loss comparison
This is where the two peptide classes diverge most dramatically in clinical outcomes. GLP-1 receptor agonists produce weight loss that is frankly remarkable by the historical standards of pharmaceutical intervention. Sermorelin produces gradual body recomposit
This comparison does not assign a generated winner or score.
- This is where the two peptide classes diverge most dramatically in clinical outcomes. GLP-1 receptor agonists produce weight loss that is frankly remarkable by the historical standards of pharmaceutical intervention. Sermorelin produces gradual body recomposition that is genuinely useful but operates on a different scale entirely.
- Semaglutide at the 2.4mg dose in the STEP 1 trial produced an average weight loss of 14.9% of body weight over 68 weeks. STEP 2, conducted in people with type 2 diabetes, showed 9.6% average weight loss. STEP 4, which extended the protocol, showed continued weight loss in responders. Tirzepatide at the 15mg dose in SURMOUNT-1 produced an average weight loss of 22.5% over 72 weeks, with a significant proportion of participants losing 25% or more. These are not modest improvements. These are results that outperform bariatric surgery for some patients. The average GLP-1 weight loss per month breaks down how the weekly losses accumulate and what realistic monthly expectations look like.
- Sermorelin does not produce weight loss in this magnitude or on this timeline. What it does is shift body composition over months by increasing GH and IGF-1, which promotes muscle protein synthesis and fat mobilization, particularly visceral fat. Studies on GHRH analogs consistently show improvements in lean mass and reductions in body fat percentage in GH-deficient adults, but these are body recomposition effects rather than dramatic scale weight loss. A person starting sermorelin at 200 pounds might see two to four pounds of fat loss over several months while simultaneously gaining muscle, resulting in a scale weight change that understates the metabolic improvement. For those whose primary concern is rapid, visible results, tirzepatide before and after results and men before and after tirzepatide show the dramatic body changes GLP-1 medications can produce, while sermorelin before and after documentation shows the more gradual, composition-focused improvements. This is a completely
- Head-to-head clinical trials comparing sermorelin directly to GLP-1 medications do not exist in the published literature. The patient populations are different, the indications are different, and the study designs would be challenging to justify given the distinct mechanisms. What we have is parallel evidence, robust for GLP-1 from large phase 3 trials, and moderate for sermorelin from smaller studies and real-world protocols. Neither body of evidence tells us which is "better" in an absolute sense, because that framing misses the point. They address different problems.
- Factor
- Sermorelin
- Semaglutide
- Tirzepatide
- Retatrutide
- Mechanism
- GHRH analog, pituitary GH stimulation
- GLP-1R agonist
- GLP-1R + GIP agonist
- GLP-1R + GIP + glucagon agonist
- Average weight loss
- 2-5% (body recomposition)
- 15-17%
- 20-22.5%
- ~24% (phase 2)
- Muscle preservation
- Excellent (promotes lean mass)
- Poor without resistance training
- Moderate
- Under study
- Dosing frequency
- Daily
- Weekly
- Results timeline
- 3-6 months for body comp
- 4-8 weeks for appetite change
- Primary side effects
- Injection site, mild headache
- Nausea, GI distress
- Nausea, GI distress, potential muscle loss
- FDA status (adults)
- Off-label
- Approved (obesity, T2D)
- Phase 3 trials ongoing
- The table above makes clear that these are not competing products targeting the same indication. They are complementary tools addressing different aspects of metabolic health. For those trying to decide between semaglutide and tirzepatide specifically, the semaglutide vs tirzepatide side effects comparison covers the nuances, and the semaglutide dosage calculator helps with dose management once you are underway.
- Who gets better results with which? If your goal is significant, scale-weight fat loss, particularly if you have 50 or more pounds to lose, GLP-1 medications produce results that sermorelin simply cannot match. If your goal is body recomposition, anti-aging, improved recovery, better sleep, and modest fat reduction without dramatic caloric restriction, sermorelin is more appropriate. If you are on GLP-1 medications and concerned about muscle loss alongside fat loss, that is where sermorelin can serve as a complement rather than a competitor.